Abstract library

36 results for "Hill".
#53 The rise and fall of chromogranin A as an indicator for NET
Introduction: There is now general awareness that treatment with proton pump inhibitors (ppi) may cause moderate rises in circulating concentrations of gastrin and/or chromogranin A (CgA), thus decreasing the specificity of these markers in the diagnosis of neuroendocrine tumors (NETs). Due to their high efficacy, proton pump inhibitors (ppi) are one of the most frequently prescribed classes of drugs worldwide. Several studies in various countries report that 30% or more of in-patients have been prescribed ppi. Patients who are suspected of having a neuroendocrine tumor (NET) often have gastrointestinal (GI) symptoms for which ppi are prescribed and therefore they may be already taking ppi when their first blood sample is assayed for NET markers. We previously encountered a case of extreme rise in CgA which flagged the possibility of a NET, but was later shown to be due to ppi therapy alone. We present CgA and gastrin data in relation to ppi therapy and withdrawal for this patient. In order to see if this was an isolated incident, we audited all laboratory requests for CgA/gastrin in a two-year period and monitored those that provided details of ppi treatment/withdrawal.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Lee Armstrong
#105 A pilot study using biochemical markers to predict acrcinoid heart disease in patients with carcinoid disease
Introduction: Carcinoid heart disease (CHD) affects up to 15-70% of patients with carcinoid disease. Recent ENETS guidelines recommend regular echocardiographic assessment to screen for CHD. Chromogranin A (CgA) is a peptide widely used to monitor carcinoid disease progression. Neurokinin A is a tachykinin which may be a more sensitive measure of carcinoid disease progression and prognosis. N-terminal pro Brain Naturetic Peptide is used as a screening tool for heart failure and recent results suggest utility in the diagnosis of CHD.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Christopher Wong
#129 Grade according to Ki-67 or mitotic count in gastroenteropancreatic neuroendocrine tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (NETs) are uncommon tumors with a reported incidence of 2.5-5 per 100000 population. The recent classification system of NETs proposed by the European Neuroendocrine Tumor Society (ENETS) uses both Ki-67 labelling index and mitotic index to assign grade (low, intermediate, high). It has been adopted into routine practice but there is limited data on the relationship between these indices and their effect on classification.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#267 Plasma Somatostatin: Gastrin Ratio Improves the Diagnosis of Gastrinoma
Introduction: Fasting gastrin alone is inadequate for diagnosis of gastrinoma. Diagnosis requires confirmation of low gastric pH. Low gastric pH is associated with increased numbers of D (somatostatin) cells.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Radha Ramachandran
#294 Chromogranin B is a Prognostic Marker in NETs
Introduction: Chromogranin B (CgB) co-localizes with Chromogranin A (CgA) in the secretory granules of neuroendocrine cells. Previous studies have investigated CgA, but not CgB, as a prognostic marker in NETs.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Mr Paul R Bech
#432 Ten Years of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Evolution of Classification and Correlation with Follow-up in 50 Patients
Introduction: In the last decade, GEP-NET nomenclature has been twice reviewed. The 2000 WHO classification had poor prognostic power in well-differentiated (WD) neoplasms which led to the introduction of two new important parameters: grade and stage, by ENETS; the former became part of the new 2010 WHO classification.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Diego Ferone
#452 Clinical and Psychometric Validation of the Disease-Specific Questionnaire Module (EORTC QLQ-GINET21) in Assessing Quality of Life of Patients with Neuroendocrine Tumors
Introduction: Quality of life (QoL) is an important outcome measure in clinical trials and is increasingly being used as an endpoint. The QLQ-GINET21 is a questionnaire developed with the EORTC QoL Group but which had not previously been validated.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr John Ramage
#584 KI-67 HETEROGENEITY IN GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE TUMORS
Introduction: The neuroendocrine tumor (NET) proliferation-based grading system (ENETs/WHO) has proved reliable for prognostic stratification, however concerns exist on Ki67 heterogeneity.
Conference:
Category: Basic
Presenting Author: Dr Federica Grillo
#587 First in vitro study of Human GastroEnteroPancreatic-Neuroendocrine Tumors: comparative effect of Octreotide, Pasireotide and Everolimus.
Introduction: Recently pasireotide (PAS) and everolimus (RAD) emerged as potential therapies for neuroendocrine tumors (NETs).
Conference:
Category: Basic
Presenting Author: MD Manuela Albertelli
#669 Incidence of Second Malignancy in Patients with Neuroendocrine Tumors (NETs) of the Ileum and Colon (MGC)
Introduction: Increased incidence of second malignancy is observed in NETs (Kamp et al 2012).
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Professor Joy Ardill
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.